Further, evidence suggests that APOE-ε4, considered a risk factor toward the onset of sporadic AD, may work in concert with Aβ peptides to incite lysosomal membrane disruption, release of lysosomal enzymes, and subsequent neuronal degradation. This evidence concerns the gene APOE and Alzheimer disease.